Trial
NCT04635735
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Bristol-Myers Squibb
Condition
Relapsed/Refractory Multiple Myeloma
Intervention
Ipilimumab
Why stopped
Lack of accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-23